This relevance is highlighted by the profound restriction of GR binding sites to open chromatin sites in AR-positive prostate cancer cells (Figure 3E) (57), suggesting that GR replaces AR activity and drives enzalutamide resistance from these open chromatin sites. The gene discussed is NR3C1; the disease is Familial prostate cancer.